These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8341651)

  • 1. Lipid advanced glycosylation: pathway for lipid oxidation in vivo.
    Bucala R; Makita Z; Koschinsky T; Cerami A; Vlassara H
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6434-8. PubMed ID: 8341651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
    Bucala R
    Diabetes Res Clin Pract; 1996 Feb; 30 Suppl():123-30. PubMed ID: 8964186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of oxidative stress in the long-term glycation of LDL.
    Menzel EJ; Sobal G; Staudinger A
    Biofactors; 1997; 6(2):111-24. PubMed ID: 9259992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis.
    Makita Z; Yanagisawa K; Kuwajima S; Bucala R; Vlassara H; Koike T
    Nephrol Dial Transplant; 1996; 11 Suppl 5():31-3. PubMed ID: 9044304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein.
    Al-Abed Y; Liebich H; Voelter W; Bucala R
    J Biol Chem; 1996 Feb; 271(6):2892-6. PubMed ID: 8621676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study.
    Sobal G; Menzel J; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 2000 Oct; 63(4):177-86. PubMed ID: 11049692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
    Bucala R; Makita Z; Vega G; Grundy S; Koschinsky T; Cerami A; Vlassara H
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9441-5. PubMed ID: 7937786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies.
    Li D; Devaraj S; Fuller C; Bucala R; Jialal I
    J Lipid Res; 1996 Sep; 37(9):1978-86. PubMed ID: 8895064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density-lipoprotein (LDL)-bound flavonoids increase the resistance of LDL to oxidation and glycation under pathophysiological concentrations of glucose in vitro.
    Wu CH; Lin JA; Hsieh WC; Yen GC
    J Agric Food Chem; 2009 Jun; 57(11):5058-64. PubMed ID: 19489629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1.
    Liguori A; Abete P; Hayden JM; Cacciatore F; Rengo F; Ambrosio G; Bonaduce D; Condorelli M; Reaven PD; Napoli C
    Eur Heart J; 2001 Nov; 22(22):2075-84. PubMed ID: 11686665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis.
    Bucala R
    Trends Cardiovasc Med; 1997 Feb; 7(2):39-47. PubMed ID: 21235862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.
    Picard S; Parthasarathy S; Fruebis J; Witztum JL
    Proc Natl Acad Sci U S A; 1992 Aug; 89(15):6876-80. PubMed ID: 1495978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.
    Palinski W; Koschinsky T; Butler SW; Miller E; Vlassara H; Cerami A; Witztum JL
    Arterioscler Thromb Vasc Biol; 1995 May; 15(5):571-82. PubMed ID: 7749871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis.
    Bucala R
    Nephrol Dial Transplant; 1996; 11 Suppl 5():17-9. PubMed ID: 9044301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycation and oxidation: a role in the pathogenesis of atherosclerosis.
    Lyons TJ
    Am J Cardiol; 1993 Feb; 71(6):26B-31B. PubMed ID: 8434558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes.
    Nosadini R; Tonolo G
    Nutr Metab Cardiovasc Dis; 2011 Feb; 21(2):79-85. PubMed ID: 21186102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycated low-density lipoprotein and atherogenesis: the missing link between diabetes mellitus and hypercholesterolaemia?
    Graier WF; Kostner GM
    Eur J Clin Invest; 1997 Jun; 27(6):457-9. PubMed ID: 9229224
    [No Abstract]   [Full Text] [Related]  

  • 18. Oxidative stress and non-enzymatic glycation in IgA nephropathy.
    Vas T; Wagner Z; Jenei V; Varga Z; Kovács T; Wittmann I; Schinzel R; Balla G; Balla J; Heidland A; Nagy J
    Clin Nephrol; 2005 Nov; 64(5):343-51. PubMed ID: 16312261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower susceptibility of low density lipoprotein to in vitro oxidation in diabetic patients.
    Taus M; Ferretti G; Curatola G; Dousset N; Solèra ML; Valdiguie P
    Biochem Int; 1992 Dec; 28(5):835-42. PubMed ID: 1288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products induce crosslinking of collagen in vitro.
    Sajithlal GB; Chithra P; Chandrakasan G
    Biochim Biophys Acta; 1998 Sep; 1407(3):215-24. PubMed ID: 9748585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.